Compare ACXP & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACXP | RDI |
|---|---|---|
| Founded | 2017 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 49.0M |
| IPO Year | 2021 | 1994 |
| Metric | ACXP | RDI |
|---|---|---|
| Price | $1.36 | $1.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $95.50 | N/A |
| AVG Volume (30 Days) | 82.1K | ★ 96.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $202,988,000.00 |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $0.94 |
| 52 Week High | $8.34 | $2.41 |
| Indicator | ACXP | RDI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.22 |
| Support Level | N/A | $1.00 |
| Resistance Level | N/A | $2.41 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 4.00 |
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.